on GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
GenSight Biologics Strengthens its Regulatory Team
GenSight Biologics, a biopharmaceutical company dedicated to gene therapies, announces key appointments to its regulatory leadership team. Fang Li becomes Executive Director of Regulatory Affairs and Quality, while Sabrina Chekroun is appointed Senior Vice President. Fang Li will be based in the United States and Sabrina Chekroun in France.
These strategies are part of a growing regulatory landscape, including compassionate access authorizations in France and Israel, and an IND approval in the United States. This strengthening aims to prepare for the launch of an international Phase III trial. GenSight Biologics emphasizes its commitment to providing innovative therapies to patients with neglected diseases.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENSIGHT BIOLOGICS S.A. news